Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PanOptica, Inc.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD
Aged 50 years or older
Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye
You may not be if
No prior ocular or systemic treatment or surgery for neovascular AMD in the study eye
History of or current clinical evidence in the study eye of:
* aphakia
* diabetic macular edema
* any ocular inflammation or infections
* pathological myopia
* retinal detachment
* advanced glaucoma
* significant media opacity, including cataract
History or evidence of the following surgeries in the study eye:
* penetrating keratoplasty or vitrectomy;
* corneal transplant;
* corneal or intraocular surgery within 3 months of Screening
Uncontrolled hypertension despite use of antihypertensive medications
Participation in any investigational drug or device study, systemic or ocular, within past 3 months
Women who are pregnant or nursing
Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation
Clareo Health | Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
